Atlas Venture Fund XI, L.P. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:31 pm Sale |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Atlas Venture Fund XI, L.P. | 467,529 1.000% |
-1,496,000 (-76.19%) |
Filing |
| 2022-02-11 5:03 pm Sale |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Atlas Venture Fund XI, L.P. | 1,963,529 5.600% |
-242,883 (-11.01%) |
Filing |
| 2021-02-16 5:27 pm Sale |
2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Atlas Venture Fund XI, L.P. | 2,206,412 6.400% |
-500,000 (-18.47%) |
Filing |